Cell News and Research

RSS

Scientists uncover minute mechanism of nuclear pore complexes at molecular level

Dr. Joseph Glavy at Stevens Institute of Technology studies the smallest and most basic elements of life. The Assistant Professor of Chemical Biology runs the Glavy Lab, where advanced student scientists study the nuclear pore complexes (NPCs) in cells, observing the minutest mechanisms of life as they unfold during mitosis. The Glavy Lab's formal purpose is to study the NPC at the molecular level in the pursuit of the unknown or unexpected in the well-studied but not always well-understood nuclei of living cells.

17 Nov 2010

Garvan Institute professor receives 2010 Prime Minister's Prize for Science

Professor John Shine AO FAA, Executive Director of Sydney's Garvan Institute of Medical Research, received the 2010 Prime Minister's Prize for Science, the nation's most highly respected award for scientific achievement, in Parliament House tonight.

17 Nov 2010

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

If researchers could determine how to send signals to cells responding to a spinal cord injury, they might be able to stop one type of cell from doing additional damage at the injury site and instead, coax it into helping nerve cells grow.

17 Nov 2010

Never-smokers have better chance of surviving head and neck cancer

Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.

17 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency ("EMA") approved CTI's Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between the ages of six months and 18 years. Previously, the Pediatric Committee (the "PDCO") of the EMA adopted an opinion agreeing to the PIP and a deferral of the initiation of the clinical studies until after the drug receives EMA approval.

17 Nov 2010

Anthera places voluntary hold on A-623 Phase 2b study for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has notified the US Food and Drug Administration (FDA) that the company has placed a voluntary hold on PEARL-SC, the Phase 2b study of A-623 for the treatment of Systemic Lupus Erythematosus (lupus), due to problems found with product vials.

17 Nov 2010

New animal research identifies factors that may play key roles in depression

New animal research has identified factors, such as the stress response and immune system, that may play important roles in depression. Scientists have also found that the regulation of nerve cell signals influences depression in animals, and that new drug combinations may more effectively treat it. The findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

New layer of kidney cells can purify blood

Researchers at Eindhoven University of Technology (TU/e) and the University Medical Center Groningen have succeeded in culturing a layer of kidney cells in the lab. These cells maintained their functional properties, and are able to purify blood.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

Elsevier launches new module for scientific community

Elsevier , a world-leading publisher of scientific, technical and medical information products and services, today announced the launch of SciVerse Applications beta, a new module within the SciVerse platform that will empower the scientific community to develop and share customized solutions that advance the search and discovery process through its marketplace and developer network.

17 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

Swissmedic approves use of plasma components treated with Cerus' INTERCEPT Blood System

Cerus Corporation announced today that the Swiss regulatory body, Swissmedic, has approved the use of plasma components treated with Cerus' INTERCEPT Blood System.

17 Nov 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Cell News and Research

Scientists uncover minute mechanism of nuclear pore complexes at molecular level

Garvan Institute professor receives 2010 Prime Minister's Prize for Science

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

Never-smokers have better chance of surviving head and neck cancer

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

Anthera places voluntary hold on A-623 Phase 2b study for lupus

New animal research identifies factors that may play key roles in depression

New layer of kidney cells can purify blood

New OncoMap technique can detect point mutation in ovarian cancer

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Elsevier launches new module for scientific community

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Study: EGFR inhibtion may help treat triple negative breast cancer

Swissmedic approves use of plasma components treated with Cerus' INTERCEPT Blood System

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics